Jonathan Ledermann, MD | Authors


Rucaparib May Improve PFS in Patients With Ovarian Cancer

November 22, 2019

Jonathan Ledermann, MD, professor of oncology, UCL Cancer Institute, University College London, discusses the results of a subanalysis from the phase III ARIEL trial of rucaparib maintenance treatment for patients with recurrent ovarian carcinoma.

Phase III Results for Rucaparib in Ovarian Cancer

December 14, 2017

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses phase III results of a study of rucaparib versus placebo following response to platinum-based chemotherapy for recurrent ovarian cancer.

Toxicities Associated With Rucaparib for the Treatment of Ovarian Cancer

September 08, 2017

Jonathan Ledermann, MD, professor of medical oncology in the University College London Cancer Institute and director of Cancer Research UK and UCL Cancer Trials Centre, discusses the toxicities associated with rucaparib (Rubraca) for the treatment of ovarian cancer.